# Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma

> **NCT03279614** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 45 (estimated)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** SOX

## Key facts

- **NCT ID:** NCT03279614
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-01
- **Primary completion:** 2019-09-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2017-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03279614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03279614, "Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03279614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*